Comparing Two Progestin Birth Control Pills for High Blood Pressure After Preeclampsia
Compares drospirenone and norethindrone pills in women with high blood pressure after preeclampsia.
Key facts
- Who runs it
- Oregon Health and Science University
- Where
- Portland, United StatesSee the site
- Trial code
- Registry title
- A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 50 people, planned
- Started
- Jul 2026
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Norethindrone 0.35 MG
- Drospirenone
- Record updated
- 19 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 or older who gave birth at Oregon Health & Science University after preeclampsia and are thinking about a progestin-only pill for contraception.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Preeclampsia, or long-term high blood pressure with preeclampsia on top (with or without severe features). Admitted for the birth at Oregon Health & Science University.
Main reasons for not taking part
- Plans to use a birth control method other than a progestin-only pill
- Medical reasons not to take drospirenone or norethindrone
- Cannot check blood pressure at home after leaving the hospital
- Cannot fill in follow-up surveys by email in English
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Admission to Oregon Health \& Science University following a birth (during the same admission)
- A diagnosis of preeclampsia or chronic hypertension with superimposed preeclampsia (with or without severe features)
- Considering use of a progestin-only pill for postpartum contraception
Who cannot take part
- Planned use of a contraceptive method other than a progestin-only pill
- Contraindications to drospirenone or norethindrone
- Inability to monitor blood pressure at home after discharge
- Inability to complete follow-up surveys by email in English
Where in United States
- Oregon Health Science UniversityPortland, United StatesContact: Women's Health Research UnitNot yet recruiting
About the trial
What the trial wants to find out
This is an open-label, randomized feasibility trial in which patients admitted to Oregon Health \& Science University (OHSU) after a pregnancy complicated by preeclampsia who are considering a progestin-only pill contraception postpartum will be randomized to norethindrone or drospirenone for 6 weeks following hospital discharge.
The 2 groups in the trial
- Postpartum NorethindroneExisting treatment, for comparison
Norethindrone is a well-established progestin-only contraceptive that is considered standard of care for postpartum contraception, particularly in breastfeeding individuals. Norethindrone serves as the comparator arm representing the current standard practice for postpartum contraception in individuals with recent hypertensive disorders of pregnancy.
Treatment: Norethindrone 0.35 MG
- Postpartum DrospirenoneTreatment being tested
Drospirenone is a newer progestin-only contraceptive approved by the FDA that exhibits mineralocorticoid receptor activity that has been shown to modestly lower blood pressure in addition to serve as contraception. Drospirenone represents a novel therapeutic option that may offer superior blood pressure outcomes in postpartum individuals with hypertensive disorders unlike other progestin-only contraceptives.
Treatment: Drospirenone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia
- Plain-language title
- Comparing Two Progestin Birth Control Pills for High Blood Pressure After PreeclampsiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 December 2025